What is the recommended management and treatment for DRESS syndrome?

Management and Treatment of DRESS Syndrome

Immediately discontinue the suspected culprit drug and initiate systemic corticosteroids for all but the mildest cases, as this forms the cornerstone of DRESS management with severity-based treatment escalation for organ involvement. 1, 2

Immediate Actions

Drug Withdrawal

• Stop all suspected medications immediately upon diagnosis, as this is the single most critical intervention that determines outcomes 1, 2, 3
• When multiple drugs are potential culprits, discontinue all non-essential medications and use clinical judgment combined with timing of drug initiation (typically 2-8 weeks before symptom onset) to identify the offender 2, 3
• Common causative agents include allopurinol, anticonvulsants (especially lamotrigine), antibiotics, and anti-inflammatory agents 4, 5

Severity Assessment and Initial Workup

The 2024 international Delphi consensus established three severity grades that dictate treatment intensity 1:

Mild DRESS:

• Limited skin involvement without significant organ dysfunction 1
• No hepatic, renal, or hematologic compromise 1

Moderate DRESS:

• Extensive skin involvement with mild-to-moderate organ dysfunction 1
• Transaminases elevated but <5× upper limit of normal 1
• Creatinine elevation without acute kidney injury requiring intervention 1

Severe DRESS:

• Life-threatening organ involvement including hepatic failure (transaminases >5× ULN or coagulopathy), acute kidney injury, severe cytopenias, or multi-organ dysfunction 1
• Requires intensive care unit management 1, 3

Essential Baseline Investigations

• Complete blood count with differential (assess eosinophilia, atypical lymphocytes, cytopenias) 1, 2
• Comprehensive metabolic panel including liver enzymes, bilirubin, creatinine 1, 2
• Herpesvirus reactivation testing (HHV-6, EBV, CMV) as viral reactivation drives disease progression 4, 6
• Chest imaging if respiratory symptoms present 1, 2

Treatment Protocol by Severity

Mild DRESS

• Topical corticosteroids (high-potency) for symptomatic skin relief 2, 3
• Close outpatient monitoring with laboratory follow-up every 3-7 days 1, 2
• Systemic corticosteroids may be avoided in truly mild cases, but have a low threshold to initiate if any progression occurs 1, 2

Moderate DRESS

Systemic corticosteroids are the standard of care 1, 2, 3:

• Prednisone 0.5-1.0 mg/kg/day orally (or methylprednisolone IV equivalent) 1, 2
• Continue at full dose until clinical improvement and laboratory normalization (typically 2-4 weeks) 2
• Taper slowly over 8-12 weeks minimum to prevent rebound flares, which occur in up to 20% of cases with rapid tapering 1, 2
• Monitor for steroid-related complications and herpesvirus reactivation during treatment 4, 2

Severe DRESS

• High-dose IV methylprednisolone 1-2 mg/kg/day (or equivalent) 1, 2
• Intensive care unit admission for close monitoring and organ support 1, 3
• Multidisciplinary consultation (hepatology for liver failure, nephrology for renal involvement, hematology for severe cytopenias) 1, 2

Steroid-Resistant or Steroid-Dependent DRESS

When patients fail to respond to corticosteroids or require prolonged high-dose therapy, escalate to alternative immunosuppression 7:

Second-line options (in order of evidence strength):

• Intravenous immunoglobulin (IVIG) 2 g/kg divided over 3-5 days, particularly effective for severe cases with multi-organ involvement 7, 2
• Cyclosporine 3-5 mg/kg/day, especially useful for steroid-sparing in prolonged cases 7, 2
• Mycophenolate mofetil 1-2 g/day in divided doses for steroid-dependent patients 7
• Plasmapheresis for refractory cases, though evidence is limited to case reports 7

Emerging therapies for refractory disease include biologics (dupilumab, tocilizumab) and JAK inhibitors, but data remain limited to case series 7

Post-Acute Phase Management

Follow-Up Timeline

• Weekly laboratory monitoring (CBC, liver enzymes, creatinine) during the first month 1, 2
• Biweekly monitoring during months 2-3 1, 2
• Monthly monitoring for 6-12 months total, as late relapses and autoimmune sequelae can occur 1, 2
• Watch for development of autoimmune thyroiditis, type 1 diabetes, or lupus-like syndromes in the months following resolution 6, 2

Allergological Workup Timing

Critical pitfall to avoid: Do not perform drug allergy testing too early, as it can trigger systemic reactions and yields false results 4:

• Wait minimum 6 months after complete resolution before any skin testing (patch testing or delayed intradermal testing) 4
• If patient received systemic corticosteroids ≥10 mg prednisone-equivalent or other immunosuppressants, add an additional 4 weeks after discontinuation before testing 4
• Delayed intradermal testing shows higher sensitivity than patch testing, particularly for antibiotics and anticonvulsants 4
• Test at highest non-irritating concentrations and read at 24-72 hours, with extended readings to 96 hours and 7 days for patch tests 4

Key Clinical Pitfalls

• Premature steroid taper: The prolonged immunological dysregulation in DRESS requires extended treatment; rapid taper causes rebound in 20% of cases 4, 1, 2
• Missing herpesvirus reactivation: HHV-6 and other herpesviruses contribute to disease progression and may require antiviral therapy 4, 6
• Inadequate long-term monitoring: Autoimmune complications can emerge months after apparent resolution 6, 2
• Cross-reactivity assumptions: Aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital) show cross-reactivity, but lamotrigine does not consistently cross-react despite being in the same therapeutic class 2, 5